Probiotic supplement plus lifestyle changes for fatty liver (MASLD)
Official title: Impact of a Multi-strain Probiotic Supplementation With Lifestyle Modification on Liver Steatosis, Fibrosis, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Run by Fu Jen Catholic University Hospital · NCT07400367 · Data updated 2026-11-12
This trial will test whether taking a probiotic supplement alongside lifestyle changes can reduce liver fat, improve liver tests, and improve metabolic health in adults with MASLD.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | Fu Jen Catholic University Hospital Academic / other |
| Drugs / interventions | Methotrexate |
| Locations | 2 sites (New Taipei City and 1 other locations) |
| Status | Recruiting |
| Started | April 1, 2026 |
| Main results expected | May 2027 |
| Study ends | August 2027 |
| Registry record updated | April 6, 2026 |
| Trial ID | NCT07400367 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with ultrasound-confirmed liver steatosis, ALT ≥ 60 U/L, and at least one cardiometabolic risk factor (for example elevated BMI, hypertension, dyslipidemia, or impaired glucose) are the intended participants.
✕Probably not a fit
People with active viral hepatitis, established cirrhosis, excessive alcohol intake, recent antibiotic use, suspected autoimmune or drug-induced hepatitis, or who are taking medications that induce liver steatosis are unlikely to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults with MASLD and elevated ALT who have ultrasound-confirmed liver steatosis will receive a structured lifestyle modification program and be given either an oral probiotic product or a placebo. Key outcomes include liver steatosis and fibrosis measured by elastography, liver enzymes, and metabolic markers such as fasting glucose, HbA1c, lipids, and measures of insulin resistance. Common exclusions include viral hepatitis, cirrhosis, heavy alcohol use, recent antibiotics, autoimmune or drug-related hepatitis, and use of medications known to induce steatosis. The trial aims to determine whether adding a probiotic to lifestyle change provides measurable benefits beyond lifestyle change alone.
Why it matters
Potential benefit: If successful, adding a probiotic to lifestyle therapy could offer a low-risk, accessible way to lower liver fat and improve metabolic and liver-related measures in people with MASLD.
How similar studies have gone: Previous small trials of probiotics in NAFLD/MASLD populations have reported mixed but sometimes modest improvements in liver enzymes and steatosis, so the approach is promising but not yet definitive.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * ALT ≥ 60 U/L * Liver steatosis identified by ultrasound * Meet at least one cardiometabolic criteria: 1. BMI ≥ 25 kg/m2 (Asian ≥23) 2. Waist circumference: \> 94cm (M) 80cm(F) 3. Fasting blood glucose ≥ 100 mg/dL 4. HbA1c ≥ 5.7 5. Receiving treatment of diabetes 6. Receiving treatment of Hypertension 7. Average home blood pressure: ≥ 130/85 mmHg 8. TG ≥ 150 mg/dL 9. HDL ≤ 40 mg/dL 10. Receiving treatment of dyslipidemia Exclusion Criteria: * HBsAg(+) * Anti-HCV (+) * Cirrhosis * Excessive alcohol intake ( Male over 210g/wk; Female over 140mg/wk) * Could not rule out Autoimmune hepatitis (ANA, or AMA or ASMA (+)) * Could not rule out drug related hepatitis * Receiving drug that might induce liver steatosis: * Glucocorticoids * Amiodarone * Tamoxifen * Methotrexate * Valproate * Tetracycline * Chemotherapeutic agents * Receiving immune modulators or biologics * Receiving antibiotics within 1 month * Receiving any cancer treatment * Have diagnosis of "Catastrophic Illness" defined by Health Administration of Taiwan * eGFR\<60 * Pregnancy * Currently enrolled in other dietary or pharmacology clinical trial
Where it's running
-
Fu Jen Catholic University Hospital
New Taipei City, Taiwan Recruiting -
Fu Jen Catholic University Hospital
New Taipei City, Taiwan Not yet recruiting
Study contacts
- Study coordinator: Kuan Wei Wu
- Email: david800413@gmail.com
- Phone: +886-922-710-756
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Muscle features linked to insulin resistance and cardiometabolic risk
This study tests whether specific muscle traits and activity patterns can help explain insulin resistance and related cardiometabolic risk in healthy adults.
-
Short post-meal activity and spread-out exercise for breast cancer survivors
We will test whether short bouts of activity after meals or spreading activity through the day better lower blood sugar than no activity or a standard 30‑minute workout in sedentary, postmenopausal breast cancer survivors on aromatase inhibitors and similar women without cancer.
-
Asprosin and miRNA Profiles in Young Women with Metabolic Syndrome
This study tests whether certain blood biomarkers, including asprosin and six microRNAs, differ between young women with metabolic syndrome and healthy peers.
-
Cardiorespiratory and muscular fitness in children with obesity and autism
This study tests whether cardiorespiratory fitness and handgrip strength differ between children with obesity who have autism and those who do not, and how these fitness measures relate to body size, composition, and cardiometabolic health.
-
Prenatal Exercise to See How Cardio or Strength Training Affects Blood Sugar
This study tests whether different types and amounts of exercise during pregnancy can improve blood sugar control in women with gestational diabetes.
-
Alpelisib Challenge Test to measure insulin secretory capacity
Researchers will test a new approach to measure how much insulin the body can produce in people at various weights and with or without insulin resistance, using alpelisib around a meal test.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.